PE20220384A1 - Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares - Google Patents

Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares

Info

Publication number
PE20220384A1
PE20220384A1 PE2021001852A PE2021001852A PE20220384A1 PE 20220384 A1 PE20220384 A1 PE 20220384A1 PE 2021001852 A PE2021001852 A PE 2021001852A PE 2021001852 A PE2021001852 A PE 2021001852A PE 20220384 A1 PE20220384 A1 PE 20220384A1
Authority
PE
Peru
Prior art keywords
methods
oxymetazoline
compositions
treatment
ocular disorders
Prior art date
Application number
PE2021001852A
Other languages
English (en)
Inventor
Tina Devries
David Jacobs
Original Assignee
Rvl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rvl Pharmaceuticals Inc filed Critical Rvl Pharmaceuticals Inc
Publication of PE20220384A1 publication Critical patent/PE20220384A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una formulacion oftalmica acuosa farmaceuticamente estable que comprende clorhidrato de oximetazolina y su procedimiento de preparacion. Dicha formulacion es estable durante un periodo de al menos 24 meses, a 25°C y 40% de humedad relativa; tambien refiere metodos para tratar diversos trastornos oculares relacionados con parpados caidos, tales como ptosis, o afecciones relacionadas.
PE2021001852A 2019-05-06 2020-05-05 Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares PE20220384A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962844069P 2019-05-06 2019-05-06
US201962843819P 2019-05-06 2019-05-06
US16/715,998 US10814001B1 (en) 2019-05-06 2019-12-16 Oxymetazoline compositions
US16/716,014 US10799481B1 (en) 2019-05-06 2019-12-16 Compositions and methods for treating ocular disorders
PCT/US2020/031425 WO2020227260A1 (en) 2019-05-06 2020-05-05 Oxymetazoline compositions and methods for treating ocular disorders

Publications (1)

Publication Number Publication Date
PE20220384A1 true PE20220384A1 (es) 2022-03-18

Family

ID=72750169

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001852A PE20220384A1 (es) 2019-05-06 2020-05-05 Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares

Country Status (17)

Country Link
US (11) US10814001B1 (es)
EP (1) EP3965737A1 (es)
JP (2) JP7141420B2 (es)
KR (3) KR102410503B1 (es)
CN (2) CN117045596A (es)
AU (1) AU2020268329A1 (es)
BR (1) BR112021022404A2 (es)
CA (1) CA3139443A1 (es)
CL (1) CL2021002918A1 (es)
CO (1) CO2021015265A2 (es)
IL (1) IL287831A (es)
MA (1) MA55895A (es)
MX (1) MX2021013516A (es)
PE (1) PE20220384A1 (es)
SG (1) SG11202112272TA (es)
WO (1) WO2020227260A1 (es)
ZA (1) ZA202108950B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
WO2022187306A1 (en) 2021-03-03 2022-09-09 Voom, Llc Compositions and methods for treatment of blepharitis
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
KR20150017002A (ko) 2006-03-17 2015-02-13 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 눈용 조성물
AU2007243334A1 (en) 2006-04-26 2007-11-08 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling
US8466203B2 (en) * 2006-12-06 2013-06-18 David Choohyun Paik Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
CN101951886A (zh) * 2007-12-21 2011-01-19 先灵-普劳健康护理产品公司 增强羟甲唑啉的光稳定性
US8128960B2 (en) * 2008-03-11 2012-03-06 Alcon Research, Ltd. Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
CA2764477A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
AU2011327785A1 (en) * 2010-11-08 2013-03-07 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
JP6030067B2 (ja) 2010-12-03 2016-11-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的クリーム組成物および使用法
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
KR20150011807A (ko) 2012-05-25 2015-02-02 질리어, 인크. 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CN106031323B (zh) 2013-09-18 2020-03-17 迈康尼股份公司 用于组件的改进的存储和处理的方法、系统和设备
CA2951725C (en) 2014-06-11 2022-06-07 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US20170312335A1 (en) * 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation
EP3407976A4 (en) 2016-01-26 2019-07-17 Levation Pharma Ltd. COMPOSITIONS AND USES OF ALPHA-ADRENERGIC AGENTS
CN105997856A (zh) * 2016-06-24 2016-10-12 魏威 盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant

Also Published As

Publication number Publication date
JP2021191802A (ja) 2021-12-16
US11103482B2 (en) 2021-08-31
BR112021022404A2 (pt) 2022-01-18
JP7141420B2 (ja) 2022-09-22
MA55895A (fr) 2022-03-16
CL2021002918A1 (es) 2022-08-19
KR20200128629A (ko) 2020-11-16
IL287831A (en) 2022-01-01
EP3965737A1 (en) 2022-03-16
US20210386711A1 (en) 2021-12-16
US11541036B2 (en) 2023-01-03
ZA202108950B (en) 2023-10-25
CN117045596A (zh) 2023-11-14
MX2021013516A (es) 2022-01-24
KR20220084264A (ko) 2022-06-21
CN111888326B (zh) 2023-07-21
US20210137889A1 (en) 2021-05-13
US20210015795A1 (en) 2021-01-21
US20220257566A1 (en) 2022-08-18
US20220273621A1 (en) 2022-09-01
US10814001B1 (en) 2020-10-27
US20210212992A1 (en) 2021-07-15
US11311515B2 (en) 2022-04-26
SG11202112272TA (en) 2021-12-30
CO2021015265A2 (es) 2022-02-28
US10898573B1 (en) 2021-01-26
WO2020227260A1 (en) 2020-11-12
US11324722B2 (en) 2022-05-10
US20200353083A1 (en) 2020-11-12
KR102410503B1 (ko) 2022-06-17
US11701343B2 (en) 2023-07-18
JP2020183373A (ja) 2020-11-12
KR20240060580A (ko) 2024-05-08
AU2020268329A1 (en) 2022-01-06
US20240033250A1 (en) 2024-02-01
US10799481B1 (en) 2020-10-13
CN111888326A (zh) 2020-11-06
US20210023222A1 (en) 2021-01-28
KR102663319B1 (ko) 2024-05-03
CA3139443A1 (en) 2020-11-12
US10940138B2 (en) 2021-03-09
US20230355587A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
PE20220384A1 (es) Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
MX2021004707A (es) Nuevos compuestos antihelminticos.
BRPI0519508A2 (pt) análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase
EA201790889A1 (ru) Офтальмологический раствор
MX2019008963A (es) Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.
MX360888B (es) Formulaciones oculares para suministro de fármaco al segmento posterior del ojo.
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
BR112022001567A2 (pt) Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias.
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
EA201001326A1 (ru) Стерильные офтальмологические композиции и способ их получения
MX2022000928A (es) Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona.
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
AU2017261303A1 (en) Ophthalmic compositions
BR112021025558A2 (pt) Formulação estável de cetrorelix e processo para a preparação de uma formulação estável
EA202091725A1 (ru) Офтальмические композиции, содержащие биластин, бета-циклодекстрин и по крайней мере одно желатинирующее вещество
EA202191683A1 (ru) Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии
WO2019090010A3 (en) Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
AU2020299145A8 (en) Compositions and methods for treating eye diseases
EA201270097A1 (ru) Способ улучшения биодоступности латанопроста
PH12020500246A1 (en) Pharmaceutical compositions